Taking the Long View: LA ART for HIV Treatment and Prevention

Download All
Learn with the experts about the latest data and developments on the current and future roles of long-acting ART in HIV treatment and prevention strategies. Listen to podcasts, read ClinicalThought faculty commentaries, download slidesets and patient education sheets, or watch the on-demand multimedia module of this engaging symposium.
Babafemi Taiwo, MBBS
Program Director
Cristina Mussini, MD
Darrell H. S. Tan, MD, FRCPC, PhD

ClinicalThought

Here’s my take on incorporating the available evidence to select the right patients for HIV treatment with long-acting injectable cabotegravir plus rilpivirine.

Cristina Mussini, MD Released: July 25, 2022

In this commentary, I share the factors I consider when deciding whether or not to recommend use of the optional 4-week oral lead-in before initiating long-acting cabotegravir plus rilpivirine injections and my thoughts on every-month vs every-2-month dosing.

Babafemi Taiwo, MBBS
Program Director
Darrell H. S. Tan, MD, FRCPC, PhD
Released: August 12, 2022

To extend long-acting PrEP to all potential candidates, we must improve our ability to reach individuals wherever they routinely access health services in the community. Here are my thoughts on the barriers we will need to address as we look to the future and the potential for bringing long-acting PrEP even closer to individuals who would benefit.

Babafemi Taiwo, MBBS
Program Director
Released: September 12, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings